Idorsia Pharmaceuticals Ltd.

Drug Name	Phase	Indication	Designations	Patent
Daridorexant 10 mg	Phase 3	Insomnia Disorder	-	-
Daridorexant	Phase 3	Insomnia Disorder	-	-
Cetirizine	Phase 3	Seasonal Allergic Rhinitis	-	-
Aprocitentan 12.5 mg	Phase 3	Resistant Hypertension	-	-
Lucerastat	Phase 3	Fabry Disease	-	-
Clazosentan	Phase 3	Aneurysmal Subarachnoid Hemorrhage	-	-
tezosentan	Phase 3	Acute Heart Failure	-	-
Daridorexant 50 mg	Phase 3	Insomnia Disorder	-	-
Daridorexant 25 mg	Phase 3	Insomnia	-	-
ACT-129968	Phase 3	Seasonal Allergic Rhinitis	-	-
ACT-539313	Phase 2	Binge-Eating Disorder	-	-
ACT-541468 5 mg	Phase 2	Insomnia Disorder	-	-
ACT-709478 for oral use	Phase 2	Photosensitive Epilepsy	-	-
Aprocitentan 5 mg	Phase 2	Essential Hypertension	-	-
Clazosentan 1 mg/h	Phase 2	Aneurysmal Subarachnoid Hemorrhage	-	-
ACT-541468	Phase 2	Insomnia Disorder	-	-
ACT-774312	Phase 2	Bilateral Nasal Polyposis	-	-
ACT-280778	Phase 2	Essential Hypertension	-	-
Setipiprant	Phase 2	Asthma	-	-
Zolpidem	Phase 2	Insomnia Disorder	-	-

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Idorsia Pharmaceuticals Ltd.

Market Overview

IDIA News

Catalyst Timeline

Daridorexant 25 mg Phase 2 Results Expected

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals